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Herbal Heafth
Ads for herbal medicines are everywhere
these days, encouraging consumers to treat
themselves "the natural way" for everything
from asdtma to hypertension. What do we
really know about these products-and
what more do we need to
learn? These questions were
addressed at the Intemational
Workshop to Evaluate
Research Needs on the Use
and Safety of Medicinal.
Herbs, held 23-24 Septb
-1998._ in Raleigh, North
Carolina. The workshop was
sponsored by the NIEHS, the
National Toxicology Program
(NTP), the NIH Office of
Dietary Supplements, the
NIH Office of Research on
Women's Health, the Depart-_
ment ofHealth and Human
Services Office ofDisease Pre-
vention and Health Pro-
motion, the Food and Drug
Admition (FDA) Ofice
ofSpeial Nutrition, and the -
Society for the Advanceet
ofWomens HealdthResarc _
The worlkhop was devd-
oped to address questions2;`
about the availability and
qualityoftoxicological dataon
medicinal herbs, which are
being used in ever increasing
numbers in the United States,




to discuss the use of herbal
products, establish what
research is needed to address public health
concerns, and weigh various strategies for
carringout hisresech.
WhoUsesMedicinal Herbs?
According to Phyllis Greenberger, executive
directorofthe SocietyfortheAdvancement
ofWomen's Health Research, most U.S.
botanical product users are white, college-
-educated, middle-aged women. Many
botanical products are marketed towards
women, such as St. John's wort (Hyperium
per#ratum), which is promoted as a treat-
ment for mild depression, a condition that
affict two to three times morewomen than
men.
Mark Blumenthal, executive director of
theAmerican BotanicalCouncil, anonprof-
it education group in Austin, Texas, said
that 30% ofall U.S. adults use some type of
herbal product. Annual product sales are
expected to-reach approximately $5 billion
by the year 2000, and the market is rapidly
spreading from specialty and health food
stores into pharmacies and grocery stores.
Press coverage ofherbal remedieshashelped
fuel their phenomenal rise in popularity.
For instance, the news show 20/20covered
an artide in the 3 August 1996 issue ofthe
BritishMedicalJoumnalin which analysis of
23 clinical trials on St. John's wort showed
the plant to be more effective than placebos
in treating depression. After the show was
broadcast in June 1997, St. John's wort
rocketed from virtual anonymity to being
oneofthetopbotanicalsellersof1998.
Butalackofadequateregulation among
herbal products leads to a confusing mix of
products, offeringdiferentdosagesanddos-
ingformats, such as capsules, teas, and pills.
Greenbergersays some ofthese products are
not tested for either purity or potency.
Furthermore, each time a consumer pur-
chases a botanical product, it is uncertain
whethertheproductwillwork, oreven con-
taintheadvertsed amountofactiveingredi-
ent. Keynote speaker Norman R.
Farnsworth, director of the Program for
Collaborative Research in the Pharma-
ceutical Sciences at the University ofIllinois
at Chicago, cited a study conducted by the
Good Housekeeping Institute and present-
ed last March at the First Consumer Safety
Symposium on Dietary Supplements and
Herbal Remedies. The study looked at 10
popular St. John's wort products, 6 in cap-
sule form and 4 in liquid
X extract form, and found
i marked discrepancies-as
I much as a 17-fold difference-
in the levels of the suspected





for special pharmacognosy at
the Institute for Pharmaceutical
Biology in Munich, Germany,
described research being done
on medicinal plants in
Germany, where most herbal
products are dassified bylaw as
drugs, and must therefore meet
the same criteria for quality,
efficacy, and safety as synthetic
drugs. According to Wagner,
approximately 400 single- and
double-blind dinical trials have
already been conducted with
various standardized herbal
extracts and mixtures, with
promising results. Many of
these studies investigated
botanicals that are widely used
in the United States, such as
Ginkgo biloba, garlic (Allium
sautvum), and kava kava (Piper
methysticum).
Commission E was estab-
lished by the German govern-
ment in 1978 to evaluate herbal drugs for
safety and efficacy. The commission pub-
lished over 300 monographs, recently trans-
lated into English by the American
Botanical Council, on a number ofindivid-
ual extracts and botanical mixtures. The
monographs indude assessments ofwhether
the extracts or mixtures listed are safe and
effective for nonprescription use, and also
list side effects, contraindications, and
dosage ranges. However, the monographs
do not reference the sources used in making
those assessments, which undermines their
credibility in the eyes of many U.S.
researchers. It also makes itdifficult to eval-
uate the monographs' statements, condu-
sions, andrecommendations fromascientif-
ic perspective.
The European Scientific Cooperative
on Phytotherapy (ESCOP) is a voluntary
association of medicinal plant experts
founded in 1989. ESCOP works to
Volume 106, Number 12, December 1998 * Environmental Health Perspectives A 590.NIEHS News
advance the scientific stature of herbal
medicines and assists in harmonizing their
regulatory status within European nations.
The cooperative publishes monographs
summarizing the therapeutic uses ofvarious
medicinal plants. Unlike the Commission
E monographs, however, the ESCOP
monographs do not propose standards or
characterize plant extracts.
Sukh Dev, currently a visiting professor
at the B.R. Ambedkar Centre for
Biomedical Research at the University of
Delhi in India, spoke on the ancient Indian
tradition ofAyurvedic medicine. This tradi-
tion prescribes holistic treatments combin-
ing drugs, diet, and exercise, and employs
some 1,250 different herbs. Ayurvedic med-
icine is only one form of traditional medi-
cine that is widely practiced in India, espe-
cially among the rural populations.
Traditional practitioners may also partici-
pate in public health programs such as pro-
viding child immunizations and diagnosing
prevalent diseases such as malaria and tuber-
culosis. In Japan, meanwhile, according to
Yutaka Sashida, a professor ofchemistry at
the Tokyo University ofPharmacy and Life
Science in Japan, about 85% of doctors
combine traditional herbal remedies with
modern medicines, and botanical prescrip-
tions arecovered bymedical insurance.
Research Needs
Standardization. Most participants named
bioactive standardization as the single most
pressing research need for herbal medicines.
The first step in standardization is deter-
mining the biologically active component(s)
ofeach botanical, or some other marker by
which to judge product quality.
Standardization of medicinal herbs must
also cover many other considerations,
including the species ofplant used, harvest
schedule, storage methods, physical charac-
teristics of raw materials, methods for pro-
ducing uniform extracts, and knowing
which part of the plant (e.g., root, flower,
leaf) contains the desired bioactive com-
pounds.
Rossanne Philen, an epidemiologist
with the Centers for Disease Control and
Prevention, stressed the importance ofusing
botanicals within the context oftheir tradi-
tional use. It's easy, she said, to take the
approach that "ifa tea isgood, a concentrat-
ed capsule must be 10 times better." Floyd
Leaders, chairman and CEO of Botanical
Enterprises ofRockville, Maryland, pointed
out that many companies have westernized
herbal remedies that were once adminis-
tered as teas or soups into the pills and cap-
sules that seem to be preferred by U.S. con-
sumers-possibly to the detriment of the
efficacy oftheoriginal product.
Prioritization ofresearch needs. There
was little agreement on how to prioritize the
plants to be studied. Farnsworth called for a
more efficient approach to ranking which
plants to study first. "Why study ginseng,"
he asked, "when it's already been used for
3,000 years [with no apparent side effects]?"
But, others countered, from a public health
perspective, it makes sense to study those
botanicals that are already most widely used
and to which the most people will therefore
continue to be exposed. Still others claimed
that basing studies on the sales ofparticular
products would constitute marketing-driven
research.
Some suggested first studying those
medicinal herbs that show the most promise
for the greatest health impacts. This could
include herbs known or suspected to con-
tain toxic ingredients or, alternately, treat-
ments that target widespread health prob-
lems such as osteoporosis or arthritis, and
serious illnesses forwhich there currentlyare
no medications. David Schardt, associate
nutritionist for the Center for Science in the
Public Interest, an education and advocacy
organization in Washington, DC, suggested
studying botanicals for which "there are
already some pieces of the puzzle in place,
wherejust a little more research is needed in
order for doctors to be able to recommend
these products to patients, or at least to not
discourage their use."
Educationfor allstakehol4ers. Kenneth
D. Fisher, executive directorofthe Office of
Disease Prevention and Health Promotion,
said the medical community needs to be
better educated on the traditional uses of
medicinal herbs. This was pointed up by a
study published in the 17 June 1998 issue
of the Journal ofthe American Medical
Association (JAMA) that was cited at the
workshop. The study examined the effects
ofgarlic oil on serum lipoprotein concentra-
tions and cholesterol levels, and concluded
that "[g]arlic therapy for treatment of
hypercholesterolemia cannot be recom-
mended on the basis of this study." The
problem? The celebrated cholesterol-reduc-
ing effects of the pungent plant come only
from eating fresh garlic or the dried powder
equivalent-not the garlic oil that was used
in theJAMAstudy.
Another misconception was broached
by Lois Gold, director of the Carcinogenic
Potency Project at the NIEHS
Environmental Health Sciences Center at
the University of California at Berkeley,
who said, "Consumers seem to think
herbals are safe just because they are 'natur-
al,' and thatsynthetic chemicals pose greater
health hazards than naturally occurring
chemicals." In contrast to this assumption,
Gold said, the toxicology of natural and
synthetic chemicals is similar, with roughly
equal proportions of natural and synthetic
chemicals being shown through rodent
assays to be carcinogenic. Moreover, said
Gold, compared to other chemical expo-
sures, herbal products are taken at doses that
are relatively dose to their toxic range. They
are also often taken chronically.
Other problems identified included
haphazard record keeping by gatherers and
importers of herbs, and nonstandardized
identification techniques, both ofwhich can
result in adulterated raw materials.
Collectors must be trained to properly iden-
tify the raw materials, and must be aware of
common substitutes or look-alikes for par-
ticular plants, which can contribute to adul-
teration problems. William R. Obermeyer,
a research chemist in the Division of
Natural Products at the Center for Food
Safety and Applied Nutrition, stated that
some patent medicines being imported into
the United States, primarily from China,
contain potentially toxic substances such as
diazepam, camphor, and mercury.
Botanicals may also be contaminated with
pesticides, excreta, molds, and other adul-
terants.
With the many thousands ofbotanicals
in use today, it is important to distinguish
amongthevarious species ofplants. In addi-
tion to the myriad of common names for
different botanicals (for instance, "boneset,"
"feverwort," and "thoroughwort" are just
three ofthe nicknames for Eupatoriumper-
foliatum), plants can even have multiple
genus/species synonyms. Forexample, while
the accepted binomial for saw palmetto is
Serenoa repens, the plant is nevertheless fre-
quently referred to as Sabal serrulata, and
less frequently as Corypha repens or even
Brahea serrulata. Marriott stressed the
importance of referring to medicinal herbs
by their correct, accepted Latin binomials.
She also urgedwriters in the audience to use
the Latin binomials in medical article titles
and keywords so the articles can be more
easily and reliably retrieved by citation
search engines.
Collaboration. Common sense calls for
there to be a central organizing body to
coordinate research into botanicals-per-
haps the Office of Dietary Supplements or
the NIEHS. But, said LoriA. Love, director
of the Clinical Research and Review Staff
with the FDA Center for Food Safety and
Applied Nutrition, "Before any research can
begin, different fields ofscientific expertise,
including psychiatry, cardiology, and
endocrinology, need to be engaged in order
to frame appropriate, pertinentquestions."
Blumenthal pointed out that many of
the necessary studies on botanicals have
been conductedalready in Europe. The data
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are there, Blumenthal said; it's just a matter
of knowing where and how to find them.
But Schardt defended the desire to repro-
duce such studies in U.S. labs, pointing out
that, for example, European studies on the
efficacy of St. John's wort for treating
depression average a length of only five
weeks-even though St. John's wort can
take as long as fourweeks to have anyeffect.
He also asserted that the results of certain
studies may not be as compelling as some
daim. For instance, in response to a claim
that some 28 controlled trials of various
forms ofechinacea have been conducted in
Europe, Schardt said that most of those
studies used parenteral echinacea, which is
not available in the United States, orpropri-
etary products that also are not available to
U.S. consumers. Furthermore, Schardt said,
the results ofseveral controlled trials testing
the effects oforal echinacea supplements on
the common cold and influenza are incon-
clusive. Still, there was general agreement
among the participants that the United
States must display more willingness to
cooperate with and participate in interna-
tional research on standardization, efficacy,
andsafety.
Financial support. Many speakers felt
that the money for testing, analyzing, and
evaluating the published safety and efficacy
data on medicinal herbs should come from
the government, and looked to the FDA as
the natural choice for initiating such studies.
But Yuan-Yuan Chiu, deputy director of
the Office of New Drug Chemistry at the
FDA Center for Drug Evaluation and
Research, claimed the agency has barely
enough resources to maintain the programs
already in place, and called on the other
government agencies represented to share
their funds and resources.
Others felt that industry bears the bur-
den of responsibility for supporting
research. Pharmaceutical companies rou-
tinely spend 10-20% of their profits on
research and development, a figure that is
not borne out in the botanical industry.
But, said Loren Israelsen, executive director
ofthe Utah Natural Products Alliance, con-
trary to an editorial in the 17 September
1998 issue of the New EnglandJournal of
Medicine in which editors Marcia Angell
and Jerome Kassirer suggest the botanical
industry is not interested in research, the
industry very much wants to conduct and
collaborate on botanicals research.
Israelsen described some of the dilem-
mas faced by the industry in terms of
research incentives versus expenditures. In
order to receive FDA approval as a nonpre-
scription drug, each substance within a
given plant-not just those within the
extract used in the botanical preparation-
would need to be studied in a lengthy,
expensive process. In addition, the FDA
review process for nonprescription drugs
does not allow consideration of foreign
data. Therefore, many studies that have
already been done overseas would need to
be duplicated.
Another issue is the Dietary Supplement
Health and Education Act of 1994, which
for the first time allowed botanical manu-
facturers to label their products with claims
ofhow the product may affect the structure
or functioning of the body. With the pas-
sage of the act, many manufacturers began
conducting legitimate research in order to
formulate their daims, but some manufac-
turers indulge in "borrowed science"-
applying the results of another company's
studies to their own products, often leading
to inaccurate daims (the resultant mislabel-
ing is addressed under the Federal Food,
Drug, and Cosmetic Act). Finally, most
synthetic drugs are developed with the goal
of being patented. But with the countless
varieties ofbotanical products being sold, it
is impossible to daim market exclusivity as a
research incentive.
BotanicalsToday ... andTomorrow
Research and regulatory decisions are much
too complex to base on a single workshop.
However, most participants seemed satisfied
to have been able to voice the concerns of
their particular camps, and excited about
the evident-albeit fragmented-wealth of
expertise represented at the workshop. A
summary of several recommendations
drawn from workshop presentations and
discussions is being compiled by the
NIEHS. Of the workshop, co-organizer
H.B. Matthews said, "We've certainly set
the stage for a continuing dialogue on this
subject."
According to Israelsen, a "broad under-
standing among all interested parties ofthe
issues involved" is needed. "We need to
serve the consumer, set aside animosities,
and just do the work," he said. "The real
[goal] is that the consumers have safe botan-
ical products.
Autoimmune Disease and the
Environment
According to a study published in the
September 1997 issue of Clinical
Immunology andImmunopathology by scien-
tists at The Johns Hopkins University in
Baltimore, Maryland, at least 10 million
people in the United States are affected by
one of 80 known autoimmune diseases.
These diseases include both organ-specific
conditions, such as type I diabetes, and sys-
tem-wide diseases, such as systemic lupus
erythematosus. They range from the well-
known, such as multiple sclerosis, to the rel-
atively rare and obscure, such as Takayasu's
arteritis (which attacks the aorta and its
branches). Perhaps because of the wide
range of the health effects caused by these
diseases, little is known about their origin
and epidemiology.
In an effort to address the dearth ofeti-
ologic information on this mysterious fami-
ly of diseases, a workshop entitled Linking
Environmental Agents and Autoimmune
Diseases was held 1-3 September 1998 at
the NIEHS campus in Research Triangle
Park, North Carolina. The workshop was
jointly sponsored by the NIEHS, the EPA
National Health and Environmental Effects
Research Laboratory (NHEERL), the NIH
Office ofRare Diseases, the NIH Office of
Research on Women's Health, the National
Institute ofAllergy and Infectious Disease,
the National Institute of Diabetes and
Digestive and Kidney Diseases, the
National Institute ofArthritis, Musculo-
skeletal, and Skin Diseases, the American
Autoimmune Related Diseases Association,
and theJuvenile Diabetes Foundation.
Almost all autoimmune diseases occur
more often in women than in men; in some
ofthese diseases, more than 90% ofpatients
are female. It is not clear exactly why
women are targeted more often than men,
but estrogen is suspected to play a pivotal
role. Autoimmune diseases seem to particu-
larly attack connective tissue and the neuro-
muscular, endocrine, and gastrointestinal
systems, but are not unknown in other parts
ofthe body.
Autoimmunity occurs when the body's
immune system turns against itself. The
immune system is designed to protect the
body by producing antibodies in response
to invading microorganisms such as viruses
or bacteria. Sometimes, for reasons that are
still not fully understood, these antibodies
are directed against self-, rather than for-
eign, antigens. Such a response probably
occurs naturally in most peop le to some
extent, but for someone with a genetic pre-
disposition to autoimmune disease, bacte-
ria, viruses, toxic agents, or certain drugs
may provide the boost necessary to trigger a
full-fledged autoimmune response. Other
factors that are believed to influence the
development of autoimmune disease
indude age, gender, and reproductive status
(e.g., pregnancy).
The workshop drew over 100 scientists
from a variety of disciplines, serving as a
forum for immunologists, developmental
biologists, autoimmune specialists, epidemi-
ologists, molecular biologists, and toxicolo-
gists to define the state ofthe science, iden-
tify data gaps, and map out the research still
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